Company profile: MediBeacon
1.1 - Company Overview
Company description
- Provider of optical diagnostic solutions for non-invasive organ function measurement, including the Transdermal GFR Measurement System (TGFR) that assesses kidney function via a fluorescent tracer (Lumitrace) detected through the skin, plus TGFR Sensors and Monitors for real-time data. Also offers novel fluorescent tracer agents and highly engineered transdermal sensors.
Products and services
- Lumitrace (relmapirazin): Fluorophore-based tracer administered as an IV bolus injection, generating measurable transdermal fluorescence for kidney function assessment within the TGFR system
- Transdermal GFR Measurement System (TGFR): Clinical-grade system enabling non-invasive kidney function monitoring by detecting changes in Lumitrace fluorescence through the skin for transdermal GFR assessment
- TGFR Sensor: Optical-grade transdermal sensor measuring the intensity of Lumitrace fluorescence through the skin to assess kidney function for GFR measurement
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MediBeacon
Renibus Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics to prevent and treat kidney disease, with RBT-1 (single-dose IV before elective cardiac surgery to reduce post-operative complications; Phase 3), Veverimer (oral hydrochloric acid binder for orphan diseases), RBT-3 (iron nanoparticle to restore iron and improve blood product use in cardiac surgery and ER), RBT-9 (anti-inflammatory/antioxidant for COVID-19), and RBT-2 (oral antioxidant/antifibrotic to delay CKD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Renibus Therapeutics company profile →
A1M Pharma
HQ: Sweden
Website
- Description: Provider of alpha 1 microglobulin, a body protein that is of major importance for the body's defense against oxidative stress.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full A1M Pharma company profile →
Quanta Dialysis Technologies
HQ: United Kingdom
Website
- Description: Provider of advanced haemodialysis systems for use in the home and clinic, focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based, high-performance, compact haemodialysis system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quanta Dialysis Technologies company profile →
Allena Pharmaceuticals
HQ: United States
Website
- Description: Provider of non-systemic protein therapeutics to treat metabolic and orphan diseases, engaged in development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allena Pharmaceuticals company profile →
LTX
HQ: United States
Website
- Description: Provider of pharmaceutical therapies for critically ill patients, developing an anticoagulant for ICU patients with kidney failure undergoing continuous renal replacement therapy (CRRT), a 24/7 dialysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LTX company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MediBeacon
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MediBeacon
2.2 - Growth funds investing in similar companies to MediBeacon
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MediBeacon
4.2 - Public trading comparable groups for MediBeacon
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →